Karyopharm Therapeutics Inc. (KPTI) Form 8-K — Nov 2, 2026
$KPTIForm 8-KItems 1.01, 1.03, 2.03, 2.04, 7.01, 8.01, 9.01Filed Nov 2, 2026, 9:58 PM ET0001193125-26-444164Original filing
Karyopharm Therapeutics (KPTI) filed voluntary Chapter 11 petitions on November 2, 2026 in the U.S. Bankruptcy Court for the Southern District of Texas under a prepackaged plan supported by 100% of its funded debt holders. The plan provides for Ayrmid Ltd. (majority-owned by Highbridge funds) to serve as stalking horse bidder for a merger, with creditors receiving 55% of the reorganized company and Ayrmid's owners 45%, plus contingent value rights tied to future myelofibrosis sales of XPOVIO.
Key figures
- Debt Amount
- $110 million DIP facility (up to $55 million new money)
- Breakup fee
- 3% of Bid Protection Base
- Dip maturity
- May 1, 2027
- Exit term loan
- up to $135 million
- Dip rate roll up
- SOFR (3.00% floor) + 12.25%
- Dip rate new money
- SOFR (3.00% floor) + 9.00%
- Newco ownership ayrmid
- 45%
- Notes 2028 outstanding
- $15.6 million ($15,648,085)
- Notes 2029 outstanding
- $108.0 million ($107,974,339)
- Term loans outstanding
- $129.0 million (approx; $128,981,939)
- Minimum overbid payment
- $363.6 million
- Newco ownership creditors
- 55%
- Expected transaction close
- Q1 2027
- Royalty claims outstanding
- $113.5 million ($113,536,880)
- Minimum alternative transaction
- $335.4 million (at least $316.6 million cash)
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.